COMPARATIVE EFFICACY OF PROTON PUMP INHIBITORS VS. H2 RECEPTOR ANTAGONISTS IN THE TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE

S KHAN; A MUNEEB; MS AHMAD

doi:10.54112/bcsrj.v2024i1.1496

Authors

S KHAN Department of Gastroenterology, Khyber Medical College Peshawar, Pakistan
A MUNEEB Department of Physician, Ch. Rehmat Ali Memorial Trust Hospital, Lahore
MS AHMAD Department of Medicine, King Edward Medical University Lahore

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1496

Keywords:

Proton Pump Inhibitors, H2 Receptor Antagonists, Gastroesophageal Reflux Disease, Symptom Relief, Esophageal Healing, Treatment Efficacy

Abstract

Gastroesophageal reflux disease (GERD) is a common condition characterized by acid reflux into the esophagus, leading to symptoms such as heartburn and regurgitation. Objective: To compare the efficacy of Proton Pump Inhibitors (PPIs) and H2 Receptor Antagonists (H2RAs) in treating GERD in a cohort of 800 patients, assessing symptom relief, healing rates, and side effects. Methods: A total of 800 patients diagnosed with GERD were added to receive either PPIs (n=400) or H2RAs (n=400) for a treatment period of 8 weeks. The primary outcome was improved GERD symptoms, measured using a standardized GERD symptom questionnaire. Results: The study found that the PPI group demonstrated a significantly higher improvement in symptom relief, with 78% achieving complete symptom resolution compared to 54% in the H2RA group (p < 0.05). Esophageal healing rates were also superior in the PPI group, with 84% showing complete healing compared to 62% in the H2RA group. Furthermore, the time to symptom relief was shorter in the PPI group (average of 5 days) compared to the H2RA group (8 days). Adverse effects were minimal and comparable between the two groups, with mild headaches (8% vs. 6%) and gastrointestinal discomfort (10% vs. 9%) being the most frequently reported. Conclusion: Proton Pump Inhibitors are more effective than H2 Receptor Antagonists in relieving symptoms, accelerating symptom resolution, and promoting esophageal healing in patients with GERD. Although both treatments are generally well-tolerated, PPIs remain the preferred choice for patients requiring more potent acid suppression due to their superior efficacy.

Downloads

Download data is not yet available.

References

Denızlı R, Sakcak B, Farisoğulları N, Peker ME, Sınacı S, Kara Ö, Tanacan A, Tekın ÖM, Şahın D. The İmpact of Elevated Liver Enzymes and İntrahepatic Cholestasis of Pregnancy on the Course of COVID-19 in Pregnant Women. SN Comprehensive Clinical Medicine. 2022 Aug 11;4(1):184.

Malarkiewicz P, Nowacka U, Januszaniec A, Mankiewicz A, Kozłowski S, Issat T. Intrahepatic Cholestasis of Pregnancy during COVID-19 Pandemic. Medicina. 2024 Apr 22;60(4):676.

Holden, M.G., Schmiech, K.V., Telleria, M.M., Sun, X., Bender, W.R. and Karjane, N.W., 2024. COVID-stasis of Pregnancy: An Increased Prevalence of COVID-19 in Patients with Cholestasis. American Journal of Perinatology, 41(S 01), pp.e3286-e3292.

Fida R, Wahab S, Naz A, Shah M, Khan A. Impact of COVID-19 on the Prevalence of Intrahepatic Cholestasis of Pregnancy. Pakistan Journal of Medical & Health Sciences. 2023 May 13;17(03):543-.

Januszewski, M., Ziuzia-Januszewska, L., Kudan, M., Pluta, K., Klapaczyński, J., Wierzba, W., Maciejewski, T., Jakimiuk, A.A. and Jakimiuk, A.J., 2024. Liver damage profile in COVID-19 pregnant patients. Cell Communication and Signaling, 22(1), p.5.

Ai, L., Wei, J., Wang, S., Tan, X., Yan, L., Liu, S., Yang, L., Luo, A. and Xu, H., 2020. COVID-19 is a risk factor for severe liver damage for patients with intrahepatic cholestasis of pregnancy: a case report.

Gu, Y., Xing, Y., Zhu, J., Zeng, L. and Hu, X., 2023. Post-Coronavirus Disease 2019 (COVID-19) Liver Injury in Pregnant Women: A Retrospective Cohort Study. Clinical and Experimental Obstetrics & Gynecology, 50(11), p.248.

Can E, Oğlak SC, Ölmez F. Abnormal liver function tests in pregnant patients with COVID-19—a retrospective cohort study in a tertiary center. Ginekologia Polska. 2022;93(2):151-7.

Cai, Q.Y., Li, X., Yang, Y., Luo, X., Luo, S.J., Xiong, J., He, Z.Y., Chen, Y., Mou, Y.W., Hu, J.Y. and Yang, S., 2023. Rational use of drugs to alleviate adverse outcomes caused by COVID-19 quarantine in women with intrahepatic cholestasis of pregnancy. Frontiers in Medicine, 10, p.1122873.

Sun, Wenping, Jing Zhang, and Hongmei Liu. "Abnormal Liver Function and Blood Coagulation Function of Coronavirus Disease 2019-Infected Pregnant Women." Clinical and Experimental Obstetrics & Gynecology 50, no. 11 (2023): 244.

Binbin LI, Wen GA, Xiaoyuan XU, Jianxiang LI. Abnormal liver biochemical parameters in pregnancy during the epidemic of coronavirus disease 2019. 临床肝胆病杂志. 2024;40(1):104-9.

Cooper, K.M., Colletta, A., Asirwatham, A.M., Simas, T.A.M. and Devuni, D., 2022. COVID-19 associated liver injury: A general review with special consideration of pregnancy and obstetric outcomes. World journal of gastroenterology, 28(42), p.6017.

Zhang X, Chen Y, Salerno S, Li Y, Zhou L, Zeng X, Li H. Prediction of intrahepatic cholestasis of pregnancy in the first 20 weeks of pregnancy. The Journal of Maternal-Fetal & Neonatal Medicine. 2022 Dec 12;35(25):6329-35.

Sekulovski M, Bogdanova-Petrova S, Peshevska-Sekulovska M, Velikova T, Georgiev T. COVID-19 related liver injuries in pregnancy. World Journal of Clinical Cases. 2023 Mar 3;11(9):1918.

Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, Kohari K, Bacq Y, Bozkurt N, Brun-Furrer R, Bull L. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. The Lancet. 2019 Mar 2;393(10174):899-909.